AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2567190
Drug: Active depot
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active depot neuroleptic injections
Trial: 2567190
Drug: Placebo depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo depot neuroleptic injections
Trial: 60622
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (220 mg three times daily)
Trial: 25609338
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy tablets containing birch and/or alder or grass pollen allergoids
Trial: 21454917
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day) for the first 6 weeks
Trial: 21454917
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) alone
Trial: 18645136
Drug: High-dose UV‐A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UV‐A1 phototherapy (130 J/cm²)
Trial: 18645136
Drug: Medium-dose UV‐A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UV‐A1 phototherapy (65 J/cm²)
Trial: 18645136
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose exposure (110-150 J/cm²)
Trial: 16813176
Drug: Three-part massage
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-part massage therapy (acupoints at the head, abdomen, and back, once daily for 15 days)
Trial: 16813176
Drug: Guipi Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guipi Pills (8 pills each time, thrice daily for 15 days)
Trial: 16813176
Drug: Three-part massage
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-part massage therapy
Trial: 12932752
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy for up to 24 months
Trial: 11038198
Drug: Subtotal thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtotal thyroid resection (total remnant < 4 ml)
Trial: 8777834
Drug: Intravenous noradrenaline
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous noradrenaline infusion
Trial: 3903822
Drug: Combined estrogen-androgen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen-androgen preparation (E-A)
Trial: 22770377
Drug: Salidroside (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salidroside (600 mg/day)
Trial: 20581169
Drug: Imatinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 200 mg orally once daily (increased to 400 mg if well tolerated)
Trial: 11419566
Drug: Metrifonate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (30 to 60 mg by weight or a 50-mg fixed dose once daily)
Trial: 9521401
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin) 5,000 U once daily
Trial: 9521401
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin 5,000 U twice daily
Trial: 2681717
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin
Trial: 2685951
Drug: Uniphyllin (UP)
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyllin (UP) taken as a single dose at bedtime
Trial: 2685951
Drug: Slophyllin (SP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slophyllin (SP) taken twice daily
Trial: 789170
Drug: N‐acetyl‐L‐glutamine aluminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐acetyl‐L‐glutamine aluminum complex (KW)
Trial: 29392459
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored therapy plan and additional home visits (Intervention Group)
Trial: 29392459
Drug: Standard German
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard German neurological treatment (Control Group)
Trial: 24851039
Drug: Spasmofen rectal
RxNorm normalized name: atropine sulfate / hyoscyamine sulfate / phenobarbital / scopolamine hydrobromide Oral Tablet [Spasmolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spasmofen rectal suppository (100 mg ketoprofen and 10 mg hyoscine butylbromide)
Trial: 24851039
Drug: Ketorolac IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac IV (30 mg/2 mL)
Trial: 24851039
Drug: Spasmofen rectal
RxNorm normalized name: atropine sulfate / hyoscyamine sulfate / phenobarbital / scopolamine hydrobromide Oral Tablet [Spasmolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spasmofen rectal suppository
Trial: 2023538
Drug: Pyridostigmine (PD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD), 120 mg administered orally
Trial: 2023538
Drug: Placebo, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two tablets administered orally
Trial: 2023538
Drug: Saline, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, 1 mL injected as an IV bolus
Trial: 6266897
Drug: pivmecillinam/pivampicillin (pivmecillinam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam/pivampicillin (pivmecillinam 200 mg plus pivampicillin 250 mg) three times daily (14 patients)
Trial: 6266897
Drug: pivmecillinam alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam alone (400 mg three times daily) (12 patients)
Trial: 31253621
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) alone
Trial: 9706932
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (1 g every 4 h)
Trial: 10155674
Drug: Late rescue
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late rescue surfactant therapy
Trial: 10155674
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment of severely ill neonates
Trial: 10155674
Drug: Multiple-dose treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose treatments
Trial: 10155674
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment surfactant therapy
Trial: 10155674
Drug: Prophylaxis surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis surfactant therapy
Trial: 10155674
Drug: Introduction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Introduction of porcine-derived lung surfactant (PLS) therapy
Trial: 10155674
Drug: PLS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLS therapy
Trial: 10155674
Drug: Costs for
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costs for PLS therapy
Trial: 10155674
Drug: Additional costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional costs of PLS therapy per additional survivor
Trial: 2350628
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy and total lymphoid irradiation with 750 cGy for severe aplastic anemia patients.
Trial: 2350628
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy and single dose total body irradiation with 750-850 cGy for leukemia patients.
Trial: 2350628
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy and fractionated total body irradiation with 1320 cGy for leukemia patients.
Trial: 15037412
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of rosiglitazone daily for 3 months
Trial: 3551675
Drug: Epidural pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural pethidine 25 mg
Trial: 31367733
Drug: Combined program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined program of textured lunch gatherings with oral and physical exercises (12-week program, twice a week)
Trial: 25544263
Drug: neostigmine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine (70 μg/kg) and atropine (0.4 mg per mg neostigmine)
Trial: 24085261
Drug: CYP3A4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4 inhibitor (ketoconazole 400 mg daily for 10 days)
Trial: 24085261
Drug: CYP3A4 inducer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A4 inducer (rifampicin 600 mg daily for 14 days)
Trial: 24085261
Drug: Midostaurin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin (single dose 100 mg and multiple doses 50 mg twice daily)
Trial: 21392603
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (intravenous immunoglobulin and aspirin)
Trial: 27784021
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (monthly or individualized dosing)
Trial: 27784021
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (delayed responders)
Trial: 24888911
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Foley catheter and low-dose vaginal misoprostol
Trial: 24888911
Drug: Low-dose vaginal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaginal misoprostol alone
Trial: 18654870
Drug: Threefold diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threefold diluted smallpox vaccine
Trial: 18654870
Drug: Sixfold diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sixfold diluted smallpox vaccine
Trial: 15971472
Drug: Fluticasone/salmeterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol combination via Diskus (n = 39) for 1 year
Trial: 10556107
Drug: alpha(1)‐antitrypsin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha(1)‐antitrypsin infusion (250 mg/kg)
Trial: 10556107
Drug: albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin infusion (625 mg/kg)
Trial: 8818828
Drug: Oral co‐trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co‐trimoxazole 960 mg od or three times a week for primary and secondary prophylaxis
Trial: 8818828
Drug: Co‐trimoxazole 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co‐trimoxazole 120 mg/kg/day in divided doses for 21 days
Trial: 8818828
Drug: Oral dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dapsone with trimethoprim, oral clindamycin with primaquine, or IV pentamidine for mild or moderately severe disease
Trial: 23484334
Drug: Single-dose Rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Rifampicin, Ofloxacin and Minocycline (ROM)
Trial: 17638804
Drug: Single-dose cefmetazole
RxNorm normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefmetazole just before skin incision
Trial: 17638804
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of cefmetazole (1 dose just before skin incision and 2 additional doses every 8 hours)
Trial: 15047650
Drug: Vitamin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin therapy (vitamins C and E)
Trial: 9796323
Drug: Heparin-coated Palmaz-Schatz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated Palmaz-Schatz stent
Trial: 25451627
Drug: Jyoti meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jyoti meditation (8-week program with weekly 90-minute classes)
Trial: 23331510
Drug: 600,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 IU of Intramuscular vitamin D3
Trial: 21702900
Drug: Oxytocin (OT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OT) - 24 IU intranasal administration
Trial: 17977662
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine 6 mg (total 48 mg over 4 days)
Trial: 16671426
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Craniotomy for evacuation)
Trial: 10781452
Drug: Protocol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol group (goal-oriented hemodynamic therapy)
Trial: 8630614
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline sulphate via Turbuhaler (TBH)
Trial: 8630614
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline sulphate via pMDI
Trial: 8630614
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulphate via pMDI
Trial: 8630614
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulphate via Turbuhaler (TBH)
Trial: 1477308
Drug: 2-mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg dose of trihexyphenidyl
Trial: 6398984
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Na (44 mmol) daily diet
Trial: 3539897
Drug: Neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron therapy (d(15)+Be neutrons)
Trial: 3539897
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy (megavoltage photons)
Trial: 29644408
Drug: Biomarker-driven maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-driven maintenance therapy
Trial: 29644408
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction treatment
Trial: 23933108
Drug: Integrated Behavior
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Behavior Therapy for Selective Mutism (IBTSM)
Trial: 20462395
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin B (0.2 mg/mL) eye drops every 2 hours for 21 days and subconjunctival fluconazole (2 mg/mL) injections
Trial: 18405818
Drug: Extraction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction therapy (removal of 4 premolars)
Trial: 18405818
Drug: Nonextraction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextraction therapy with air-rotor stripping (ARS)
Trial: 14633755
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg every 4 h for 24 h)
Trial: 10724301
Drug: Salbutamol delivered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol delivered via conventional pressurized metered-dose inhaler (MDI)
Trial: 6385444
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg trimethoprim
Trial: 30712923
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg once daily
Trial: 30806492
Drug: Acceptance-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-Based Treatment (ABT)
Trial: 20824976
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil supplementation (20 mL daily) during late pregnancy and first six months of lactation
Trial: 18821156
Drug: Allopurinol (XO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (XO inhibitor)
Trial: 9642600
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (Group 1) with bupivacaine 0.75% and intravenous midazolam and fentanyl.
Trial: 9642600
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia (Group 2) with intravenous methohexital followed by retrobulbar block with an equal mixture of lidocaine 2% and bupivacaine 0.75% plus hyaluronidase 150 units.
Trial: 9642600
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (Group 1)
Trial: 7506007
Drug: Serum potassium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum potassium < 3.5 mmol/L
Trial: 351600
Drug: Fludilat (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludilat (3 tablets per day for 3 months)
Trial: 29916929
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3 g diluted in 45 mL normal saline, applied after cementation)
Trial: 29916929
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA (1 g prior to tourniquet inflation and 1 g at closure)
Trial: 17258423
Drug: Hydroxyzine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 1.5 mg/kg
Trial: 3301980
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (200 mg), administered five times per day for 5 days
Trial: 28857425
Drug: MCP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP (30 billion CFUs per sachet, 2 sachets daily for 4 weeks) and omega-3 fatty acid (2 g daily for 8 weeks)
Trial: 24767875
Drug: Aspirin (624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (624 mg once daily for 6 months)
Trial: 24767875
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 6 months)
Trial: 19773525
Drug: Teduglutide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide (2.5 to 80 mg, daily subcutaneous administration)
Trial: 12881377
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mammography and physical examination
Trial: 8826153
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment (10 weekly sessions of 15 minutes' duration)
Trial: 3582466
Drug: Enprofylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (1 mg/kg body weight over 10 min) with terbutaline pretreatment (4 micrograms/kg body weight)
Trial: 3582466
Drug: Enprofylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (1 mg/kg body weight over 10 min) with placebo pretreatment
Trial: 30289578
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application (eMedHAT)
Trial: 28858247
Drug: Probiotic (10⁸
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (10⁸ CFUs of L. reuteri DSM 17938)
Trial: 20718754
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (granisetron and dexamethasone)
Trial: 17716750
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (40 children)
Trial: 15817818
Drug: Clopidogrel (300‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300‐mg loading dose and 75‐mg maintenance dose)
Trial: 9882033
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg o.m. pantoprazole
Trial: 9882033
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg o.m. pantoprazole
Trial: 9882033
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg b.d. pantoprazole
Trial: 2898901
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (control group IV)
Trial: 28739782
Drug: PZA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZA (10 or 25 mg/kg) plus allopurinol (100 mg daily)
Trial: 20450369
Drug: AMSA injection
RxNorm normalized name: m-AMSA
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMSA injection
Trial: 9401313
Drug: Augmentation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation therapy with triiodothyronine (T3)